Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. [electronic resource]
Producer: 20100115Description: 72-83 p. digitalISSN:- 1530-0293
- APACHE
- Adult
- Aged
- Bacterial Infections -- diagnosis
- Cohort Studies
- Critical Care -- methods
- Critical Illness -- mortality
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Hospital Mortality -- trends
- Humans
- Infusions, Intravenous
- Intensive Care Units
- Lipid A -- administration & dosage
- Male
- Maximum Tolerated Dose
- Middle Aged
- Prospective Studies
- Risk Assessment
- Sepsis -- diagnosis
- Survival Analysis
- Toll-Like Receptor 4 -- antagonists & inhibitors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.